BACKGROUND: Identification of diagnostic and prognostic biomarkers is a research priority for the improved management of pancreatic ductal adenocarcinoma (PDAC). Insulin-like growth factor binding protein 2 (IGFBP2) and mesothelin (MSLN) have shown potential as serum biomarkers in other cancers, but have not been adequately studied in PDAC. METHODS: Serum IGFBP2 and MSLN levels were quantified by enzyme-linked immunosorbent assay (ELISA) in a cohort of 84 PDAC patients, 84 healthy control subjects and 40 chronic pancreatitis (ChPT) patients. Regression models related IGFBP2 and MSLN levels to diagnosis, gender, age, stage and survival. RESULTS: IGFPB2 and MSLN serum levels were diagnostic for PDAC in age-adjusted models (P = 0.032 and P = 0.002, respectively) when compared with ChPT and healthy control samples. At a 95% specificity threshold, the sensitivity for IGFBP2 was 22% and the sensitivity for MSLN was 17%. Neither protein approached the diagnostic accuracy of CA 19-9. However, IGFBP2 or MSLN or both correctly identified 18 of the 28 samples misidentified by CA 19-9. In age-adjusted models, neither serum IGFBP2 (P = 0.36) nor MSLN (P = 0.29) were significant predictors of survival. DISCUSSION: Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel.
BACKGROUND: Identification of diagnostic and prognostic biomarkers is a research priority for the improved management of pancreatic ductal adenocarcinoma (PDAC). Insulin-like growth factor binding protein 2 (IGFBP2) and mesothelin (MSLN) have shown potential as serum biomarkers in other cancers, but have not been adequately studied in PDAC. METHODS: Serum IGFBP2 and MSLN levels were quantified by enzyme-linked immunosorbent assay (ELISA) in a cohort of 84 PDAC patients, 84 healthy control subjects and 40 chronic pancreatitis (ChPT) patients. Regression models related IGFBP2 and MSLN levels to diagnosis, gender, age, stage and survival. RESULTS: IGFPB2 and MSLN serum levels were diagnostic for PDAC in age-adjusted models (P = 0.032 and P = 0.002, respectively) when compared with ChPT and healthy control samples. At a 95% specificity threshold, the sensitivity for IGFBP2 was 22% and the sensitivity for MSLN was 17%. Neither protein approached the diagnostic accuracy of CA 19-9. However, IGFBP2 or MSLN or both correctly identified 18 of the 28 samples misidentified by CA 19-9. In age-adjusted models, neither serum IGFBP2 (P = 0.36) nor MSLN (P = 0.29) were significant predictors of survival. DISCUSSION: Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel.
Authors: P Argani; C Iacobuzio-Donahue; B Ryu; C Rosty; M Goggins; R E Wilentz; S R Murugesan; S D Leach; E Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: Ru Chen; Sheng Pan; Eugene C Yi; Samuel Donohoe; Mary P Bronner; John D Potter; David R Goodlett; Ruedi Aebersold; Teresa A Brentnall Journal: Proteomics Date: 2006-07 Impact factor: 3.984
Authors: Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen Journal: PLoS One Date: 2012-07-06 Impact factor: 3.240
Authors: Longhao Sun; Xuebin Zhang; Qianqian Song; Liang Liu; Elizabeth Forbes; Weijun Tian; Zhixiang Zhang; Ya'an Kang; Huamin Wang; Jason B Fleming; Boris C Pasche; Wei Zhang Journal: Cancer Lett Date: 2020-12-10 Impact factor: 8.679